Released Nov 2, 2021, after the close
10-Q filed Nov 2, 2021, 33 days after period end · 0001558370-21-014076
Q3 2021 · 10-Q
Revenue$21.54M$21.54M +17.2% vs Q3 2020−18.0% vs Q2 2021
Net Income-$20.95M-$20.95M N/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.12-$0.12 N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$19,785,000N/M
Operating Cash Flowderived-$10,297,000N/M
Free Cash Flowderived-$10,467,000N/M
Margins · derived
Operating margin-91.8%−16.9 pt vs Q3 2020
Net margin-97.3%−20.2 pt vs Q3 2020
What the release said
The release
Same quarter
| Metric | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|---|
| Revenue | $21.54M | $18.39M | $20.86M | $4.87M |
| Net Income | -$20.95M | -$14.17M | -$11.49M | -$23.77M |
| EPS Diluted | -$0.12 | -$0.08 | -$0.07 | -$0.14 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR